公开(公告)号：PT1734041E

公开(公告)日：2011-01-25

申请号：PT06015189

申请日：2002-07-25

Applicant: PORTOLA PHARM INC

Inventor： HUANG WOLIN ,  SCARBOROUGH ROBERT M ,  JANTZEN HANS-MICHAEL ,  SEDLOCK DAVID M ,  MARLOWE CHARLES K ,  KANE-MAGUIRE KIM A

IPC: C07D239/96 ,  C07D409/14 ,  A61K31/16 ,  A61K31/175 ,  A61K31/381 ,  A61K31/4035 ,  A61K31/4196 ,  A61K31/4725 ,  A61K31/519 ,  A61K31/54 ,  A61K31/64 ,  A61P7/02 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P9/14 ,  A61P43/00 ,  C07D209/48 ,  C07D213/70 ,  C07D239/22 ,  C07D239/50 ,  C07D333/34 ,  C07D401/04 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D487/04 ,  C07D495/04 ,  C07D521/00

公开(公告)号：CL2009002040A1

公开(公告)日：2010-09-10

申请号：CL2009002040

申请日：2009-11-05

Applicant: PORTOLA PHARM INC

Inventor： SHARP EMMA ,  QUEGAN LOUISA JANE ,  PANDEY ANJALI ,  WANG JUAN ,  NIEDER MATTHEW ,  HUANG WOLIN

IPC: A61K31/517 ,  A61P9/00 ,  C07D409/12

Abstract: Sales de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonilurea; formas cristalinas de dichas sales; método de preparación; composición farmacéutica, útil para prevenir o tratar trombosis y condiciones patológicas relacionadas con trombosis.

公开(公告)号：ZA200907493B

公开(公告)日：2010-07-28

申请号：ZA200907493

申请日：2009-10-26

Applicant: PORTOLA PHARM INC

Inventor： SHARP EMMA ,  QUEGAN LOUISA JANE ,  PANDEY ANJALI ,  WANG JUAN ,  NIEDER MATTHEW ,  HUANG WOLIN

IPC: A61K20100101 ,  C07D20100101

Abstract: The present invention provides novel sulfonylurea salts of a salt of formula (I) and polymorph forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a salt of formula (I) or a pharmaceutically acceptable form thereof.

公开(公告)号：MX2009011836A

公开(公告)日：2010-05-20

申请号：MX2009011836

申请日：2008-05-02

Applicant: PORTOLA PHARM INC

Inventor： PANDEY ANJALI ,  SHARP EMMA ,  QUEGAN LOUISA JANE ,  WANG JUAN ,  NIEDER MATTHEW ,  HUANG WOLIN

IPC: C07D409/12 ,  A61K31/517

Abstract: La presente invención proporciona sales de sulfonilurea novedosas de una sal de la fórmula (I) y formas polimorfas de la misma. Los compuestos en sus diferentes formas son efectivos inhibidores del receptor de plaquetas ADP y pueden ser utilizadas en varias composiciones farmacéuticas, y son particularmente efectivas para la prevención y/o tratamiento de enfermedades cardiovasculares, particularmente esas enfermedades relacionadas con la trombosis. La presente invención también proporciona un método para preparar dichos compuestos y formas y para prevenir o tratar la trombosis y los padecimientos relacionados con la trombosis en un mamífero que comprenden el paso de administrar una cantidad terapéuticamente efectiva de una sal de la fórmula (I) o una forma farmacéuticamente aceptable de la misma.

公开(公告)号：CA2742601A1

公开(公告)日：2010-05-14

申请号：CA2742601

申请日：2009-11-04

Applicant: PORTOLA PHARM INC

Inventor： SHARP EMMA ,  QUEGAN LOUISA JANE ,  PANDEY ANJALI ,  WANG JUAN ,  NIEDER MATTHEW ,  HUANG WOLIN

IPC: C07D409/12 ,  A61K31/517 ,  A61P7/02

Abstract: The present invention provides novel sulfonylurea salts of a salt of formula (I) \ and polymorph forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a salt of formula (I) or a pharmaceutically acceptable form thereof.

公开(公告)号：PL1668002T3

公开(公告)日：2010-02-26

申请号：PL04789522

申请日：2004-09-29

Applicant: PORTOLA PHARM INC

Inventor： SCARBOROUGH ROBERT M ,  HUANG WOLIN ,  PANDEY ANJALI ,  BAUER SHAWN M ,  ZHANG XIAOMING ,  JIA ZHAOZHONG J

IPC: C07D409/12 ,  A61K20060101 ,  A61K31/517 ,  A61P7/02 ,  C07D409/14

公开(公告)号：CA2960692A1

公开(公告)日：2009-12-03

申请号：CA2960692

申请日：2009-04-16

Applicant: PORTOLA PHARM INC

Inventor： BAUER SHAWN M ,  JIA ZHAOZHONG J ,  SONG YONGHONG ,  XU QING ,  MEHROTRA MUKUND ,  ROSE JACK W ,  HUANG WOLIN ,  VENKATARAMANI CHANDRASEKAR ,  PANDEY ANJALI

IPC: C07D239/48 ,  A61K31/505 ,  A61K31/506 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D417/12

Abstract: The present specification is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present specification is also directed to intermediates used in making such compounds, the preparation of such a compound, methods for inhibition of syk and/or JAK kinase activity, methods for inhibition of the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma. The present specification is also directed to pharmaceutical compositions containing such a compound and which are formulated for topical administration.

公开(公告)号：AT448222T

公开(公告)日：2009-11-15

申请号：AT04789522

申请日：2004-09-29

Applicant: PORTOLA PHARM INC

Inventor： SCARBOROUGH ROBERT ,  HUANG WOLIN ,  PANDEY ANJALI ,  BAUER SHAWN ,  ZHANG XIAOMING ,  JIA ZHAOZHONG

IPC: C07D409/12 ,  A61K20060101 ,  A61K31/517 ,  A61P7/02 ,  C07D409/14

Abstract: 2,4-Dioxo-3-quinazolinylaryl sulfonylurea compounds having the formula: wherein R is a member selected from the group consisting of H and C 1-6 alkyl; R 1 is a member selected from the group consisting of H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-5 cycloalkyl and C 3-5 cycloalkyl-alkyl; R 2 is a member selected from the group consisting of H, halogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 alkoxy, cyano and -C(O)R 2a , wherein R 2a is a member selected from the group consisting of C 1-6 alkoxy and (C 1-6 alkyl) 0-2 amino; L is a 1 to 3 carbon linking group selected from the group consisting of -CH 2 -, -CH(CH 3 )-, -CH 2 CH 2 -, -CH 2 CH(CH 3 )- and -CH 2 CH 2 CH 2 -; L 1 is a linking group selected from the group consisting of a bond and -CH 2 -; L 2 is a linking group selected from the group consisting of a bond, -NH- and -CH 2 -; and Ar 1 is an aromatic ring selected from the group consisting of benzene, pyridine and pyrimidine; are provided. The compounds are useful for the inhibition of ADP-platelet aggregation, particularly in the treatment of thrombosis and thrombosis related conditions or disorders.

公开(公告)号：CA2686221A1

公开(公告)日：2008-11-13

申请号：CA2686221

申请日：2008-05-02

Applicant: PORTOLA PHARM INC

Inventor： HUANG WOLIN ,  NIEDER MATTHEW ,  QUEGAN LOUISA JANE ,  SHARP EMMA ,  WANG JUAN ,  PANDEY ANJALI

IPC: C07D409/12 ,  A61K31/517

Abstract: The present invention provides novel sulfonylurea salts of a salt of form ula (I) and polymorph forms thereof. The compounds in their various forms ar e effective platelet ADP receptor inhibitors and may be used in various phar maceutical compositions, and are particularly effective for the prevention a nd/or treatment of cardiovascular diseases, particularly those diseases rela ted to thrombosis. The invention also provides a method for preparing such c ompounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therap eutically effective amount of a salt of formula (I) or a pharmaceutically ac ceptable form thereof.

公开(公告)号：AU2008247457A1

公开(公告)日：2008-11-13

申请号：AU2008247457

申请日：2008-05-02

Applicant: PORTOLA PHARM INC

Inventor： SHARP EMMA ,  NIEDER MATTHEW ,  WANG JUAN ,  PANDEY ANJALI ,  HUANG WOLIN ,  QUEGAN LOISA JANE

IPC: A61K31/517 ,  C07D409/12

Abstract: The present invention provides novel sulfonylurea salts of a salt of formula (I) and polymorph forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a salt of formula (I) or a pharmaceutically acceptable form thereof.